lactate dehydrogenase inhibitors (Leidos Biomedical Research/Vanderbilt Univ/UPenn/Univ New Mexico/Univ Alabama Birmingham/NCI/NCATS)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namelactate dehydrogenase inhibitors (Leidos Biomedical Research/Vanderbilt Univ/UPenn/Univ New Mexico/Univ Alabama Birmingham/NCI/NCATS)
Drug Alias NameLDH inhibitors (Leidos Biomedical Research/Vanderbilt Univ/UPenn/Univ New Mexico/Univ Alabama Birmingham/NCI/NCATS)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLactate dehydrogenases inhibitors
TargetsLactate dehydrogenases
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLeidos Biomedical Research Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLeidos Biomedical Research IncNational Center For Advancing Translational SciencesNational Cancer Institute +[7] 
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A